Clinical trialPhase 1 / Phase 2Completed
Study to Evaluate D-1553 in Subjects With Lung Cancer
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 16 March 2021
- Ended
- 17 May 2024
- Enrollment
- 225 participants
- Sites
- 2
- Primary outcomes
- Subject incidence of Dose-limiting toxicities (DLT); Number of subjects participants with adverse events; antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 15 October 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a phase 1/2, open label study of D-1553 single agent treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic NSCLC with KRasG12C mutation
Papers 3
- Builds on itGarsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study. DOI 10.1016/j.ejca.2025.116153↗
- Builds on itGarsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-a… DOI 10.1016/s2213-2600(24)00110-3↗
- Builds on itD-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results. DOI 10.1016/j.jtho.2023.03.015↗